AI Terminal
POLAREAN IMAGING PLC
Environmental & Social Information • May 14, 2025
7850_rns_2025-05-14_1450ed05-13a6-4304-89cf-6fdc5b025f29.html
Environmental & Social Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6917I
Polarean Imaging PLC
14 May 2025
14 May 2025
Polarean Imaging Plc
("Polarean" or the "Company")
Ongoing collaboration with Philips
Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung function , notes the announcement by its partner Philips to bring advanced Xenon lung MRI to more children with chronic obstructive lung disease.
For the full announcement by Philips, please see here: Philips and Polarean advance Xenon MRI for children's lung disease | Philips
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.
Enquiries:
| Polarean Imaging Plc | www.polarean.com / www.polarean-ir.com | ||||
| Christopher von Jako, PhD, Chief Executive Officer | Via Walbrook PR | ||||
| Charles Osborne, Chief Financial Officer | |||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | ||||
| Nicholas Moore / Nick Harland / Brough Ransom / Ben Good | |||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | ||||
| Anna Dunphy / Paul McManus | Mob: +44 (0)7876 741 001 / +44 (0) 7980 541 893 | ||||
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFLFFVEFISLIE